Moderna stock climbed after the deadly hantavirus outbreak drew investors' attention to the company's ongoing infectious disease efforts.

Moderna (MRNA) stock rose 4% on Monday, extending its 12% rally on Friday. What’s behind the move: The biotech is researching vaccines to protect against hantaviruses, a group of viruses that spread to humans through exposure to rodents.

Moderna Inc MRNA shares are trading higher during Monday’s pre-market session as investors focus shifts to an emerging global health concern, a hantavirus outbreak, that has highlighted the company's specialized research pipeline.

Shares of Moderna (NASDAQ:MRNA | MRNA Price Prediction) are up roughly 6% in Monday morning trading, changing hands near $57.52 after Friday’s close of $54.35. The intraday move extends what has already been a powerful 2026 run for the mRNA pioneer.

An mRNA-based flu shot could make a huge difference in flu prevention, allowing scientists to pick a better strain match.

Moderna's early hantavirus vaccine research has boosted stock price, reflecting market interest. The vaccine is in initial stages, with potential public health benefits but years from availability.

Regulatory filings are under review in the U.S., Europe, Canada and Australia, with potential approvals expected to

Marjorie Taylor Greene and other conservative commentators have claimed that Moderna is developing a hantavirus mRNA vaccine.